{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:38:49Z","timestamp":1790163529798,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Culture of blood <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cells with chromatin\u2010modifying agents can lead to an increase in marrow repopulating cells and in the case of valproic acid increased erythroid cell colony formation. We undertook research to help understand what effects these reagents have on mobilized peripheral blood (<jats:styled-content style=\"fixed-case\">MPB<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Mobilized peripheral blood was obtained under informed consent and ethics committee approval from nine patients and allograft donors. Epigenetic modifiers valproic acid and 5\u2010aza\u20102\u2032\u2010deoxycytidine were used singly or in combination with each other and with <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>3 when culturing mobilized peripheral blood <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cells. Cultured cells were subsequently used in flow cytometry and colony\u2010forming unit assay experiments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Addition of <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>3 to the <jats:italic>in vitro<\/jats:italic> cell growth medium improved the expansion and maintained the functionality of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cells. Valproic acid and <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>3 also work synergistically to increase the numbers of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup>\/<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>36<jats:sup>+<\/jats:sup> double\u2010positive cells. We found that an apparent increase in red cell colony formation was a result of a decrease in white cell colonies, with no overall increase in red cell colonies when equivalent numbers of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> cells are plated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mobilized peripheral blood <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup> stem and progenitor cells are affected by chromatin\u2010modifying agents and <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>3 giving higher numbers of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34<jats:sup>+<\/jats:sup>\/<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>36<jats:sup>+<\/jats:sup> double\u2010positive erythroid progenitors.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.12124","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T11:03:28Z","timestamp":1390820608000},"page":"83-89","source":"Crossref","is-referenced-by-count":5,"title":["<scp>U<\/scp>se of <scp>IL<\/scp>3 and chromatin\u2010modifying reagents valproic acid and 5\u2010aza\u20102\u2032\u2010deoxycytidine to affect mobilized peripheral blood <scp>CD<\/scp>34<sup>+<\/sup> cell fate decisions"],"prefix":"10.1111","volume":"107","author":[{"given":"J.","family":"Liu","sequence":"first","affiliation":[{"name":"Scottish National Blood Transfusion Service (SNBTS) Cell Therapy Group MRC Centre for Regenerative Medicine Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Samuel","sequence":"additional","affiliation":[{"name":"Scottish National Blood Transfusion Service (SNBTS) Cell Therapy Group MRC Centre for Regenerative Medicine Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Turner","sequence":"additional","affiliation":[{"name":"Scottish National Blood Transfusion Service (SNBTS) Cell Therapy Group MRC Centre for Regenerative Medicine Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C. J.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Scottish National Blood Transfusion Service (SNBTS) Cell Therapy Group MRC Centre for Regenerative Medicine Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314567"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20178"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375386"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-53"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005512"},{"key":"e_1_2_6_7_1","first-page":"1324","article-title":"DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias","volume":"87","author":"Leone G","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.11.011"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.03.019"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.3.842.842"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.133.1.157"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90303-V"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(85)90082-7"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.04.003"},{"key":"e_1_2_6_15_1","unstructured":"British National Formulary 2013 Pharmaceutical Press London UK"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08880010390158496","article-title":"Increase of fetal hemoglobin synthesis indicating differentiation induction in children receiving valproic acid","volume":"20","author":"Kieslich M","year":"2003","journal-title":"Pediatr Hematol Oncol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341446"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvox.12124","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T16:48:53Z","timestamp":1696006133000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.12124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/vox.12124"],"URL":"https:\/\/doi.org\/10.1111\/vox.12124","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,27]]}}}